GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » 5-Day RSI

Arvinas (Arvinas) 5-Day RSI : 37.45 (As of May. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Arvinas 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-14), Arvinas's 5-Day RSI is 37.45.

The industry rank for Arvinas's 5-Day RSI or its related term are showing as below:

ARVN's 5-Day RSI is ranked better than
67.51% of 1573 companies
in the Biotechnology industry
Industry Median: 46.32 vs ARVN: 37.45

Competitive Comparison of Arvinas's 5-Day RSI

For the Biotechnology subindustry, Arvinas's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arvinas's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Arvinas's 5-Day RSI falls into.



Arvinas  (NAS:ARVN) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arvinas  (NAS:ARVN) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Arvinas 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Arvinas's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Arvinas (Arvinas) Business Description

Traded in Other Exchanges
N/A
Address
395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Executives
Ronald Peck officer: Chief Medical Officer C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor officer: Senior Vice President, Biology C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston director, officer: President and CEO C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy officer: Chief Financial Officer 322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis officer: Chief Accounting Officer C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young director C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe director, 10 percent owner C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon director C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr. director C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon director
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139